These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 455216)

  • 21. Cell kinetic effect of low dose arabinosyl cytosine.
    Baccarani M; Tazzari PL; Motta MR; Rizzi S; Fanin R; Fasola G; Damiani D; Dinota A; Tura S
    Br J Haematol; 1987 Sep; 67(1):33-7. PubMed ID: 3663521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
    Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
    Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
    Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W;
    Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
    Solary E; Caillot D; Chauffert B; Casasnovas RO; Dumas M; Maynadie M; Guy H
    J Clin Oncol; 1992 Nov; 10(11):1730-6. PubMed ID: 1357108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial].
    Benahmed M; Carde P; Laplanche A; Renaux J; Rouesse J; Spielmann M; Sancho-Garnier H
    Bull Cancer; 1985; 72(1):30-6. PubMed ID: 2580579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia.
    Rudnick SA; Cadman EC; Capizzi RL; Skeel RT; Bertino JR; McIntosh S
    Cancer; 1979 Oct; 44(4):1189-93. PubMed ID: 498009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Low-dose cytosine arabinoside (Ara-C) continuous infusion regimen for atypical nonlymphocytic leukemia--clinical study of the remission mechanism by serial chromosomal findings, colony formation and plasma Ara-C concentration].
    Tagawa M; Tomonaga M; Shibata J; Nishino K; Nonaka H; Ikeda S; Suzuyama J; Amenomori T; Matuo T; Kuriyama K
    Rinsho Ketsueki; 1984 Oct; 25(10):1606-17. PubMed ID: 6520937
    [No Abstract]   [Full Text] [Related]  

  • 28. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of continuous infusion Ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia.
    Laver J; Shearer P; Krance R; Hurwitz CA; Srivastava DK; Weinstein HJ; Mirro J
    Leuk Lymphoma; 1997 Aug; 26(5-6):589-93. PubMed ID: 9389365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR; Robbins G; Arthur K; Mayer RJ; Kufe D
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.
    Wells RJ; Feusner J; Devney R; Woods WG; Provisor AJ; Cairo MS; Odom LF; Nachman J; Jones GR; Ettinger LJ
    J Clin Oncol; 1985 Jul; 3(7):998-1004. PubMed ID: 3860629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
    Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
    Ohshima A; Yoshida K; Sato T; Miyazaki S; Yanagisawa M; Nakayama Y; Takahashi T; Mamiya S; Fukusima Y; Miura AB
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
    Nishikawa M; Morita K; Komada F; Uemura Y; Kageyama S; Minami N; Deguchi K; Shirakawa S
    Gan No Rinsho; 1990 Oct; 36(12):2204-9. PubMed ID: 2232191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
    Slevin ML; Piall EM; Aherne GW; Harvey VJ; Johnston A; Lister TA
    J Clin Oncol; 1983 Sep; 1(9):546-51. PubMed ID: 6583325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
    Crews KR; Gandhi V; Srivastava DK; Razzouk BI; Tong X; Behm FG; Plunkett W; Raimondi SC; Pui CH; Rubnitz JE; Stewart CF; Ribeiro RC
    J Clin Oncol; 2002 Oct; 20(20):4217-24. PubMed ID: 12377965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.